Crescent Biopharma (CBIO) Change in Accured Expenses (2013 - 2026)

Crescent Biopharma (CBIO) has reported Change in Accured Expenses for 14 consecutive years, with $3.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Change in Accured Expenses rose 11.89% year-over-year to $3.0 million; the TTM figure through Jun 2026 stood at $464000.0 (down 92.96% YoY), while the FY2025 annual figure was $5.4 million, up 3333.7% from the prior year.
• Change in Accured Expenses rose to $3.0 million in Q2 2026 per CBIO's latest filing, from -$3.5 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $3.0 million in Q2 2026 and bottomed at -$3.5 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $76141.8 across 5 years, with a median of -$98051.0 in 2023.
• On a YoY basis, Change in Accured Expenses climbed as much as 2630.88% in 2024 and fell as far as 869.97% in 2024.
• Crescent Biopharma's Change in Accured Expenses stood at $1.2 million in 2022, then slumped by 107.27% to -$85820.0 in 2023, then jumped by 2630.88% to $2.2 million in 2024, then plunged by 148.76% to -$1.1 million in 2025, then jumped by 380.83% to $3.0 million in 2026.
• Business Quant data shows CBIO's Change in Accured Expenses at $3.0 million in Q2 2026, -$3.5 million in Q1 2026, and -$1.1 million in Q4 2025.